Prediction of postoperative prognoses by gene expression profiling in patients with primary resected lung cancer

2014 Fiscal Year Final Research Report

• Project/Area Number: 24592098
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Thoracic surgery
• Research Institution: Toho University (2013-2014); Kitasato University (2012)
• Principal Investigator: IYODA Akira 東邦大学, 医学部, 教授 (10302548)
• Co-Investigator(Kenkyū-buntansha): SATOH Yukitoshi 北里大学, 医学部, 教授 (90321637) ; HATA Yoshinobu 東邦大学, 医学部, 准教授 (90349910) ; TAMAKI Kazuyoshi 東邦大学, 医学部, 助教 (80385799) ; SATO Fumitomo 東邦大学, 医学部, 助教 (30385736) ; OTSUKA Hajime 東邦大学, 医学部, 助教 (70408855) ; MAKINO Takashi 東邦大学, 医学部, 助教 (30459797)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: 肺癌 / 個別化 / 予後 / システムの構築

Outline of Final Research Achievements

We analyzed LCNEC gene expression, gene mutation and immunohistochemical expression of known molecular targets and compared expression to that of lung adenocarcinomas. We analyzed 26 patients with primary LCNEC and 40 patients with adenocarcinoma (AC). We evaluated immunohistochemical (IHC) expression for topoisomerase I, II (TOPO1, 2), excision repair cross-complementing gene 1 (ERCC1), class III beta tubulin (TUBB3) and EGFR mutation (L858R) and gene mutation for EGFR using direct DNA sequencing and Scorpion-ARMS. There was a significant difference in IHC expression for TOPO2 and EGFR between LCNEC and AC. EGFR gene mutation was greater in the AC group, with no EGFR mutation in the LCNEC group. On the IHC expression of TOPO1, ERCC1, and TUBB3, there were no significant differences between LCNEC and AC.

Free Research Field

医歯薬学